Bio Saga Blog - A Chronicle of Life Sciences & Informatics

Courtesy jobsinsciences.com Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company that was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development. Job Description :  The candidate will be responsible for design and conduct of pharmacokinetic studies and application of various in vivo/in situ techniques to study clearance mechanisms, tissue distribution and brain permeability etc. He will be involved in pharmacokinetic/toxicokinetic data interpretation, PK/PD analysis, monitoring PK/DM studies at external CROs, compiling reports for IND submissions and supervising and training junior scientists. He will be responsible for designing and conducting in vitro cell permeability and drug metabol...

Courtesy jobsinsciences.com Research Associate position Molecular Biology at Piramal Life Sciences Research Associate Piramal Life Sciences Ltd Experience: 1 – 2 Years Compensation:Rupees 2,00,000 – 2,25,000 Education: UG – B.Sc – Bio-Chemistry,B.Tech/B.E. – Bio-Chemistry/Bio-Technology PG – M.Sc – Bio-Chemistry,M.Tech – Bio-Chemistry/Bio-Technology Job Description • Responsible for performing research and development experiments for projects and products, in collaboration with others. • Regularly exercises technical discretion in the [...] Principal Investigator/ Senior Principal Investigator – Neuroscience at Syngene International Ltd Principal Investigator/Senior Principal Investigator for Neuroscience Syngene International Limited Experience: 5 – 10 Years Compensation:Rupees 6,00,000 – 9,00,000 Education:UG – Any Graduate – Any Specialization,Graduation Not Required PG – Any PG Course – Any Specialization,Post Graduation Not Required Job Description Qualification: Ph.D. in P...

Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion , plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. "This strategic action will advance Abbott into the leading market position in India , one of the world's most attractive and rapidly growing markets," said Miles D. White , chairman and chief executive officer, Abbott. ...

Indian generics firm Piramal Healthcare says it " has no intention to dilute current ownership levels, " but has not commented on rumours that it is in talks with French firm Sanofi Aventis. Speculation emerged last week in an article where it was claimed that Sanofi was willing to pay a premium for a “ significant stake ” in Piramal and had already completed a due diligence review of the deal. In response, the Indian firm’s share price jumped some 17 per cent when the story broke.When contacted Piramal would not elaborate on the statement but, while most observers view the comments as scotching last week’s rumours, the lack of an outright denial of the Sanofi deal and careful choice of words still leave the possibility of an outright sale. While Sanofi would not comment, the $2bn (€1.6bn) price tag that emerged on earlier speculation that GlaxoSmithKline (GSK) was interested in Piramal, would fit with recent statements by CEO Christopher Viebacher tha...

Nicholas Piramal India Limited ("NPIL", name proposed to be changed to Piramal Healthcare Limited) is one of India's largest pharmaceutical companies, with a growth track record of above 30% CAGR since 1988. NPIL had consolidated revenues of US$602 million in 2006-07. The Company is currently ranked 4th in the Indian market with a diverse product portfolio spanning nine therapeutic areas. The Company is also one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia. NPIL is listed in India on the National Stock Exchange (Ticker: NICOLASPIR) and the Bombay Stock Exchange (Ticker: 500302). The name change from Nicholas Piramal India Limited to Piramal Healthcare Limited is subject to approval by the Company's shareholders and Central Government.